News

With this approval, for the first time, approximately 6,000 people with CF ages 12 years and older who have one F508del mutation and one minimal function mutation (F/MF)

This is the first pediatric approval for ULTOMIRIS. Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to

The Company expects to report top-line results from CONTESSA in the third quarter of 2020. Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class

The FDA approval was based on data from the DECLARE-TIMI 58 CV outcomes trial (CVOT). It is claimed to be the largest sodium-glucose cotransporter 2 (SGLT2) inhibitor CVOT

As per the terms of the deal, Sartorius Stedim will be acquiring Danaher’s label-free biomolecular characterization, chromatography hardware and resins, and the SoloHill business. The chromatography business is

In addition, George Golumbeski, Ph.D., a champion of innovation and former Executive Vice President of Celgene, has been appointed Chairman of the Verseau Board of Directors. Verseau is

Under the deal, Bavarian Nordic will purchase the manufacturing and global rights related to travel vaccines Rabipur/RabAvert to prevent rabies and Encepur to prevent TBE. The deal includes

The Prescription Drug User Fee Act (PDUFA) date for trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast

Horizon Therapeutics has initiated an open-label clinical trial evaluating the use of KRYSTEXXA (pegloticase injection) in adults with chronic gout refractory to conventional therapies – also known as